Who owns Zogenix?

Top 10 Owners of Zogenix Inc

Stockholder Stake Shares owned
Morgan Stanley & Co. LLC 7.37% 4,114,512
BlackRock Fund Advisors 7.26% 4,049,379
The Vanguard Group, Inc. 7.09% 3,956,557
Cadian Capital Management LP 5.69% 3,175,431

How many employees does zogenix have?

Company Growth (employees)

Employees (est.) (Dec 2019) 141 (+57%)
Website Visits (Apr 2021) 7.2 k
Revenue (FY, 2020) $13.6 M (+274%)
Share Price (Aug 2021) $14.8 (+2%)
Cybersecurity rating A More

Where is Zogenix based?

the United States
Zogenix is based in the United States and has additional offices in Europe and Japan.

Is Fintepla approved?

The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy.

When was zogenix founded?

In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products. Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006.

Is zogenix a good company?

Great company, everyone is very smart and dedicated. The people at Zogenix are amazing. Culture is very important to the company and the leadership keeps culture in mind before making large business decisions. There is so much potential for Zogenix coming in the future.

Is zogenix a buy?

Zogenix has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Is Dravet syndrome curable?

Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include clobazam (Onfi, Frisium) and valproic acid (Depakote, Depakene).

What kind of drug is Fintepla?

Fintepla is a prescription medicine used to treat the seizures associated with Dravet syndrome in patients 2 years of age and older. Fintepla is a federally controlled substance (C-IV) because it contains fenfluramine.

What is Dravet syndrome?

Definition. Dravet syndrome, previously called severe myoclonic epilepsy of infancy (SMEI), is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.

Is Zgnx stock a buy?

There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Zogenix stock.

What is Dravet Syndrome?